Development and assessment of nano drug delivery systems for combined delivery of rosuvastatin and ezetimibe
10.4196/kjpp.2024.28.3.275
- Author:
Ali Metwally MOHAMED
1
;
El-Yamani Ibrahim EL-ZAWAHRY
;
Maher Amer ALI
;
Diaa Farrag IBRAHIM
;
Shereen Ahmed SABRY
;
Omnia Mohamed SARHAN
Author Information
1. Department of Zoology, Faculty of Science, Al-Azhar University, Cairo 11651, Egypt
- Publication Type:Original Article
- From:The Korean Journal of Physiology and Pharmacology
2024;28(3):275-284
- CountryRepublic of Korea
- Language:English
-
Abstract:
Worldwide, cardiovascular disease is the main cause of death, which accordingly increased by hyperlipidemia. Hyperlipidemia therapy can include lifestyle changes and medications to control cholesterol levels. Statins are the medications of the first choice for dealing with lipid abnormalities. Rosuvastatin founds to control high lipid levels by hindering liver production of cholesterol and to achieve the targeted levels of low-density lipoprotein cholesterol, another lipid lowering agents named ezetimibe may be used as an added therapy. Both rosuvastatin and ezetimibe have low bioavailability which will stand as barrier to decrease cholesterol levels, because of such depictions, formulations of this combined therapy in nanotechnology will be of a great assistance. Our study demonstrated preparations of nanoparticles of this combined therapy, showing their physical characterizations, and examined their behavior in laboratory conditions and vivo habitation. The mean particle size was uniform, polydispersity index and zeta potential of formulations were found to be in the ranges of (0.181–0.72) and (–13.4 to –6.24), respectively. Acceptable limits of entrapment efficiency were affirmed with appearance of spherical and uniform nanoparticles. In vitro testing showed a sustained release of drug exceeded 90% over 24 h. In vivo study revealed an enhanced dissolution and bioavailability from loaded nanoparticles, which was evidenced by calculated pharmacokinetic parameters using triton for hyperlipidemia induction. Stability studies were performed and assured that the formulations are kept the same up to one month. Therefore, nano formulations is a suitable transporter for combined therapy of rosuvastatin and ezetimibe with improvement in their dissolution and bioavailability.
